中国药业2017，Vol.26Issue(21)：35-38,4.DOI:10.3969/j.issn.1006-4931.2017.21.013
急性缺血性脑卒中超早期阿替普酶静脉溶栓155例临床研究
Clinical Study on Ultra Early Intravenous Thrombolysis with Alteplase for Treating Acute Ischemic Stroke in 155 Cases
摘要
Abstract
Objective To observe the clinical efficacy and safety of intravenous thrombolysis with recombinant tissue plasminogn activator ( alteplase ) for treating patients with acute ischemic stroke within 4. 5 h, and analyze the factors influencing the prognosis. Methods Totally 234 patients with acute ischemic stroke within 4. 5 h from July 2014 and August 2016 admitted to the hospital were selected, and divided into the thrombolysis group ( n=155 ) and the control group ( n=79 ) . The thrombolysis group was given intravenous throm-bolysis with alteplase, while the control group was not treated with thrombolytic therapy. The NIHSS and mRS scores, cerebral hemor-rhage conversion and mortality were compared between the two groups after treatment. Results 90 d after treatment, the difference of mRS score between thrombolytic group and control group was statistically significant ( P < 0. 05 ) . There was no significant difference in incidence rate of cerebral hemorrhage and mortality between the two groups ( P > 0. 05 ) . 90 d after thrombolytic therapy, the results of multivariate Logistic regression analysis of mRS score showed that thrombolysis was a protective factor, but taking anticoagulant drugs, high mRS score and high NIHSS score at admission were the risk factors for poor prognosis. Conclusion Intravenous thrombolysis with alteplase for treating patients with acute ischemic stroke within 4. 5 h can reduce disability rate and does not increase the risk of cere-bral hemorrhage and death. Taking anticoagulant drugs, high mRS score and high NIHSS score at admission are risk factors for poor prognosis.关键词
阿替普酶/溶栓治疗/急性缺血性脑卒中/预后Key words
alteplase/intravenous thrombolysis/acute ischemic stroke/prognosis分类
医药卫生引用本文复制引用
王蕾,姜帅,何柳,方升,徐广会,朱曦,龚蕉椒,杨珊珊,张仲..急性缺血性脑卒中超早期阿替普酶静脉溶栓155例临床研究[J].中国药业,2017,26(21):35-38,4.基金项目
四川省成都市科技惠民技术研发项目[ 2015-HM01-00240-SF ]. （）
